<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03754244</url>
  </required_header>
  <id_info>
    <org_study_id>TQB3456-I-01</org_study_id>
    <nct_id>NCT03754244</nct_id>
  </id_info>
  <brief_title>A Phase I Study of TQ-B3456 on Tolerance and Pharmacokinetics</brief_title>
  <official_title>A Phase I Study of TQ-B3456 on Tolerance and Pharmacokinetics</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chia Tai Tianqing Pharmaceutical Group Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chia Tai Tianqing Pharmaceutical Group Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To study the pharmacokinetic characteristics of TQ-B3456 in the human body, recommend a
      reasonable regimen for subsequent research.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 20, 2018</start_date>
  <completion_date type="Anticipated">May 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose-Limiting Toxicities（DLT）</measure>
    <time_frame>Baseline up to 28 days</time_frame>
    <description>an adverse event cccurring after initiation of TQ-B3456 that met any following criteria：
＞=Grade 3 of non-hematology toxicity
Grade 4 hematology toxicity</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Non-small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>TQB3456</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>p.o. qd</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TQB3456</intervention_name>
    <description>Observe the safety and pk when the subjects take TQB3456 p.o. qd</description>
    <arm_group_label>TQB3456</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        - progressive or metastatic non-small cell lung cancer that diagnosed Pathologically or
        cytologically diagnosed patients who have received EGFR tyrosine kinase inhibitor
        monotherapy (e.g., gefetinib, erlotinib, ecotinib, afatinib) for disease progression EGFR
        T790M mutation was confirmed ECOG PS≤1 Adequate blood cell counts, kidney function and
        liver function Patients should participate in the study voluntarily and sign informed
        consent

        Exclusion Criteria:

        Patients with non-small-cell lung cancer who have received osimertinib or other raw
        materials or preparations for EGFRT790M mutant drugs Hypertension (systolic BP ≥140 mmHg,
        diastolic BP ≥90 mmHg) still uncontrollable by one medication; Hepatitis B virus patients
        with active replication (DNA&gt; 500 cps / mL), hepatitis C; Patients with immunodeficiency,
        including HIV positive or other acquired, congenital immunodeficiency disease, or organ
        transplant history

        -
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>No. 241 Huaihai West Road, Xuhui District, Shanghai</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200030</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>bao hui han, doctor</last_name>
      <phone>13917833343</phone>
      <email>18930858216@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>November 23, 2018</study_first_submitted>
  <study_first_submitted_qc>November 23, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 27, 2018</study_first_posted>
  <last_update_submitted>April 27, 2019</last_update_submitted>
  <last_update_submitted_qc>April 27, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 30, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

